Literature DB >> 22144494

Lsr2 peptides of Mycobacterium leprae show hierarchical responses in lymphoproliferative assays, with selective recognition by patients with anergic lepromatous leprosy.

Mehervani Chaduvula1, A Murtaza, Namita Misra, N P Shankar Narayan, V Ramesh, H K Prasad, Rajni Rani, R K Chinnadurai, Indira Nath.   

Abstract

Lsr2 protein of Mycobacterium leprae was shown earlier to elicit B and T cell responses in leprosy patients (20, 28). Lymphoproliferation to M. leprae and Lsr2 antigens was observed in >70% of tuberculoid (T) patients and in 16 and 34% of lepromatous (L) patients, respectively. We focused on the M. leprae nonresponders in the lepromatous group using 22 synthetic Lsr2 peptides (end-to-end peptides A to F and overlapping peptides p1 to p16) in in vitro T cell responses. A total of 125 leprosy and 13 tuberculosis patients and 19 healthy controls from the area of endemicity (here, healthy controls, or HC) were investigated. The highest responses were observed (67 to 100%) in HC for all peptides except p1 to p3, and the lowest was observed in tuberculosis patients. Significant differences in lymphoproliferation were observed in T, L, and HC groups (analysis of variance [ANOVA], P = 0.000 to 0.015) for all end-to-end peptides except B and for p5 and p7 to p10. Hierarchical recognition between lepromatous and tuberculoid leprosy was noted for p8 (P < 0.05) and between the HC and L groups for p7 to p10, p15, and p16 (P < 0.005 to P < 0.02). Significant lymphoproliferation was observed to peptides A to F and p1 to p9, p11, p12, p15, p16 (P = 0.000 to 0.001) with 40% responding to peptides C and p16 in L patients. Lepromatous patients also showed significantly higher levels of a gamma interferon (IFN-γ) response to peptide C than to other peptides (P < 0.05). Major histocompatibility complex (MHC) class II bias for peptide recognition was not observed. These studies indicate that Lsr2 has multiple T cell epitopes that induce in vitro T cell responses in the highly infective lepromatous leprosy patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22144494      PMCID: PMC3264286          DOI: 10.1128/IAI.05384-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment.

Authors:  P Sharma; R S Misra; H K Kar; A Mukherjee; D Poricha; H Kaur; R Mukherjee; R Rani
Journal:  Lepr Rev       Date:  2000-06       Impact factor: 0.537

2.  Structural basis for recognition of AT-rich DNA by unrelated xenogeneic silencing proteins.

Authors:  Blair R G Gordon; Yifei Li; Atina Cote; Matthew T Weirauch; Pengfei Ding; Timothy R Hughes; William Wiley Navarre; Bin Xia; Jun Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-14       Impact factor: 11.205

3.  Human T cell responses to peptides of the Mycobacterium leprae 45-kD serine-rich antigen.

Authors:  S Brahmbhatt; R Hussain; S Zafar; G Dawood; T H M Ottenhoff; J W Drijfhout; G Bothamley; S Smith; F V Lopez; H M Dockrell
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

4.  Classification of leprosy according to immunity. A five-group system.

Authors:  D S Ridley; W H Jopling
Journal:  Int J Lepr Other Mycobact Dis       Date:  1966 Jul-Sep

5.  T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy.

Authors:  A Haregewoin; T Godal; A S Mustafa; A Belehu; T Yemaneberhan
Journal:  Nature       Date:  1983-05-26       Impact factor: 49.962

6.  Serological specificity of phenolic glycolipid I from Mycobacterium leprae and use in serodiagnosis of leprosy.

Authors:  S N Cho; D L Yanagihara; S W Hunter; R H Gelber; P J Brennan
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

7.  Comparative analysis of B- and T-cell epitopes of Mycobacterium leprae and Mycobacterium tuberculosis culture filtrate protein 10.

Authors:  John S Spencer; Hee Jin Kim; Angela M Marques; Mercedes Gonzalez-Juarerro; Monica C B S Lima; Varalakshmi D Vissa; Richard W Truman; Maria Laura Gennaro; Sang-Nae Cho; Stewart T Cole; Patrick J Brennan
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

8.  A novel phenolic glycolipid from Mycobacterium leprae possibly involved in immunogenicity and pathogenicity.

Authors:  S W Hunter; P J Brennan
Journal:  J Bacteriol       Date:  1981-09       Impact factor: 3.490

9.  Evidence for the presence of M. leprae reactive T lymphocytes in patients with lepromatous leprosy.

Authors:  I Nath; M Sathish; T Jayaraman; L K Bhutani; A K Sharma
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

10.  Natural suppressor cells in human leprosy: the role of HLA-D-identical peripheral lymphocytes and macrophages in the in vitro modulation of lymphoproliferative responses.

Authors:  I Nath; J J Van Rood; N K Mehra; M C Vaidya
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

View more
  4 in total

1.  Lsr2 of Mycobacterium leprae and its synthetic peptides elicit restitution of T cell responses in erythema nodosum leprosum and reversal reactions in patients with lepromatous leprosy.

Authors:  Chaman Saini; H K Prasad; Rajni Rani; A Murtaza; Namita Misra; N P Shanker Narayan; Indira Nath
Journal:  Clin Vaccine Immunol       Date:  2013-02-27

2.  Increase in TGF-β secreting CD4⁺CD25⁺ FOXP3⁺ T regulatory cells in anergic lepromatous leprosy patients.

Authors:  Chaman Saini; Venkatesh Ramesh; Indira Nath
Journal:  PLoS Negl Trop Dis       Date:  2014-01-16

3.  CD4+ Th17 cells discriminate clinical types and constitute a third subset of non Th1, Non Th2 T cells in human leprosy.

Authors:  Chaman Saini; V Ramesh; Indira Nath
Journal:  PLoS Negl Trop Dis       Date:  2013-07-25

4.  Predicting HLA CD4 Immunogenicity in Human Populations.

Authors:  Sandeep Kumar Dhanda; Edita Karosiene; Lindy Edwards; Alba Grifoni; Sinu Paul; Massimo Andreatta; Daniela Weiskopf; John Sidney; Morten Nielsen; Bjoern Peters; Alessandro Sette
Journal:  Front Immunol       Date:  2018-06-14       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.